Alto Neuroscience Stock Discussion

$Alto Neuroscience (ANRO.US)$
Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach
Monday, 28th April at 8:03 am
– Identified and prospectively replicated an EEG-based biomarker for placebo response in MDD –
– New data strengthen the mechanistic link between ALTO-300 and the EEG biomarker being used for patient selection; biomarker signature induced by activating 5-HT2C or depleting dopamine directly –
– Preclini...

$Alto Neuroscience (ANRO.US)$
Alto Neuroscience Secures 4-Year Cash Runway as Multiple Phase 2 Trials Advance

$Alto Neuroscience (ANRO.US)$ this one needs volume

$Alto Neuroscience (ANRO.US)$
The commercial potential is noteworthy for several reasons:
The treatment-resistant depression market represents approximately 30% of MDD patients, creating a substantial addressable market for adjunctive therapies.
The biomarker-guided approach could significantly improve treatment outcomes by identifying likely responders, potentially commanding premium pricing compared to traditional antidepressants.
EEG biomarkers provide an objective, m...

$Alto Neuroscience (ANRO.US)$
Revolutionary Depression Treatment Patent: How Alto's EEG Biomarker Could Transform Patient Care

$Alto Neuroscience (ANRO.US)$
Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial
Wednesday, 12th February at 8:03 am
– Interim analysis resulted in a recommendation to continue the study with a total targeted biomarker population of ~200 patients in the final analysis sample –
– Topline results are expected in mid-2026 –
– The company recently reported an estimated preliminary 2024 year-end cash balance of approximately ...

$Alto Neuroscience (ANRO.US)$
Clinical Trial Success: Alto's Novel Depression Treatment Hits Key Milestone in Phase 2b Study

$Alto Neuroscience (ANRO.US)$
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
Wednesday, 11th December at 8:03 am
– Data generated from Alto's precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion –
– New preclinical data from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for...

$BARK Inc (BARK.US)$
<- Blackrock ->
$Alto Neuroscience (ANRO.US)$
sec.gov/Archive...

$Alto Neuroscience (ANRO.US)$ go fly